THE United States yesterday approved the world’s first vaccine for the respiratory syncytial virus (RSV), the culmination of a decades-long hunt to protect vulnerable people from the common illness.
Drugmaker GSK’s Arexvy was green-lighted for adults aged 60 and older, with similar shots from other makers including Pfizer and Moderna expected to follow soon.